The ADMET Toolkit: Impact on Compound Design and Optimisation

Date:

October 14, 2024

Time (ET):

4:00 PM

Webinar Highlights

In this webinar, the speakers will cover:

What is ADMET and why is it critical to drug discovery?
Why is (predicted) human PK and exposure so key to success?
What are the key ADMET challenges?
How to design a fit-for-purpose screening cascade?
How to anticipate/identify ADMET challenges and develop adapted solutions?

Featuring Insights from

Rob Riley

,

PhD

Independent

ADME & DMPK Expert

Dr. Rob Riley is a highly motivated, seasoned science, project, and people leader, and proven drug hunter with >30 years experience in Biopharmaceutical Research & Development in the major therapeutic areas.

Tom Pesnot

,

PhD

Concept Life Sciences

Drug Discovery Services Director

Thomas (Tom) Pesnot, PhD is Drug Discovery Services Director at Concept Life Sciences since 2024. He has gained over 15 years' experience of leading drug discovery programmes in the academic, biotech, and CRO sectors, and contributed to the development of multiple clinical candidates and marketed drugs.

Concept Life Sciences

Concept Life Sciences is a leading contract research organization (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges across a broad range of therapeutic areas and modalities.

Topics

Pharmacology

DMPK

The ADMET Toolkit: Impact on Compound Design and Optimisation

Webinar Highlights

Featuring Insights from

Rob Riley

,

PhD

Tom Pesnot

,

PhD

Sponsored by

Concept Life Sciences

Topics

Watch Now

Related Content

AI-Ready, Lab-Proven: A New Standard for High-Throughput Antibody Characterization

Leveraging In Vitro Permeation Testing: Emerging Roles in Discovery and Regulatory Science

Enhancing Clinical Predictability through Human Disease-relevant Preclinical Models in CNS and Muscle Drug Discovery

Organoid Meets Microelectrode Array (MEA) - Accelerating Drug Discovery and Development

Overcome the Multiple Challenges of Neutralizing Antibodies in Cancer Therapy Using Innovative Phage Display Technologies

COMPLi HBS Legislation Series: France

Leveraging Programmable CRISPR-Associated Transposases for Next-Generation Genome Engineering

The 3D DILI Model of Success - from Biological Relevance to Industry Application

APS Physiology in Disease Modeling and Drug Development Roundtable

From Genetic Validation to Relevant Target Engagement: Small Molecule Inhibitor Binding to 17Œ≤HSD13

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Protein-Protein Interaction (PPI) Landscape - Sequence-to-Affinity Heatmaps for High-Throughput Antibody Optimization

Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance

In Vivo panCAR Therapy Using Circular RNA for the Treatment of Autoimmune Disease

From Single Domain to Single B: Leveraging Biointron's Expertise for Antibody Discovery Success

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Launch Event: Propelling Boundaries - Innovative Technologies in Early Drug Discovery

Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology

Cell-Based Assays for Immuno-oncology

Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection

CAR Finder - A Platform for Rapid CAR T Cell Screening

Structure is Strategy: Integrating Cryo‑EM, X‑ray, NMR and HDX‑MS for Precision Drug Discovery

De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms

The Use of Vascular Access Buttons in Rabbits for PK/TK Studies

Leveraging In Vitro Permeation Testing: Emerging Roles in Discovery and Regulatory Science

AI-Ready, Lab-Proven: A New Standard for High-Throughput Antibody Characterization

Recent Advances in Crystalline Polymorphism Research in Drug Development

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

New Approach Methodologies (NAMs): Key Considerations and Applications

Enhancing Clinical Predictability through Human Disease-relevant Preclinical Models in CNS and Muscle Drug Discovery

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

hiPSC-Cardiomyocyte Platforms Enabling Comprehensive Cardiac Toxicity and Drug Efficacy Evaluation

Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI

Innovative Rabbit Antibodies and Engineering for Therapeutics and Diagnostics

High-Quality Mobilized Leukopaks to Enhance Your Cell and Gene Therapy Research and Development

Advancing Your Innovation: Navigating the Complexity of Stable Cell Line Development

Licensing Biological Materials: Crucial Considerations for Preclinical Researchers

Spatial Biology and the Gastrointestinal Tract: Unveiling Cellular Landscapes and Disease Mechanisms

Meeting Ethical & Regulatory Requirements When Using Human Biological Specimens

Reprogramming the Brain Tumor Microenvironment to Enhance Anti-Tumor Immunity

Challenges and Opportunities for Treatment of Metastatic Breast Cancer

Illuminating Immunohistochemistry: Right-sizing Your Validation and Regulatory Strategy

A New Approach to Vector-Free CRISPR Editing Starting From Single Cells

Hematopoietic Stem Cell Fitness and Function During Sickle Cell Disease

Bringing Oncology Intelligence to Early Drug Development With AI-Powered Response Predictions

Hormonal and Chromosomal Influences on Autoimmunity and Lupus

Illuminating Immunohistochemistry: From Biomarker to Clinical Trial Assay

Molecular Signals Mediating Increases in Muscle Size and Function

Applications of Human Intestinal Organoid Cultures in Drug Discovery

Next-Generation Safety Assessment Tools for Advancing In Vivo to In Vitro Translation

How to Better Predict Potential Drug Interactions Early in the Discovery Process

A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy

Revolutionizing Immunotherapy Research with 3D, Multiplexed Cryo-fluorescence Tomography

Spatial Phenotyping: A Revolutionary Approach to Biomarker Discovery for Cancer Immunotherapy

Evaluation of Novel Therapies Using Spontaneous Seizure Models

Longitudinal Plasma Samples: Paving the Way for Precision Oncology

Fast-Forward Your Custom Antibody Generation With Four Bio-Rad Services

Targeting Proteomics to Decipher Biology for the Drug Development Pipeline

Molecule Transport across Cell Membranes: Electrochemical Quantification at the Microscale

Rethink your Impurity Analysis Strategy

Analyzing the Suppressive TME in in Vitro Based Assays

Targeting T Cells Within the Cancer Immunity Cycle

Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle

Intestinal Toxicity Assessment with Patient-Derived Organoids

A Novel, All-Human Hepatic Triculture System